Aull & Monroe Investment Management Corp Has $7.57 Million Stock Holdings in Eli Lilly and Company $LLY

Key Points

• Aull & Monroe Investment Management Corp reduced its stake in Eli Lilly and Company by 3.6%, holding $7.57 million worth of stock, which constitutes 4.1% of its total investment portfolio.
• Insider purchasing activity included Director Jamere Jackson acquiring 200 shares for about $127,912, increasing his ownership by 2.17% to nearly $6 million.
• Recent analyst reports have downgraded Eli Lilly's price targets, with Morgan Stanley lowering it to $1,023 while maintaining an "overweight" rating.

Aull & Monroe Investment Management Corp reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,707 shares of the company's stock after selling 360 shares during the period. Eli Lilly and Company accounts for approximately 4.1% of Aull & Monroe Investment Management Corp's investment portfolio, making the stock its biggest position. Aull & Monroe Investment Management Corp's holdings in Eli Lilly and Company were worth $7,567,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Brighton Jones LLC raised its position in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Covestor Ltd raised its position in shares of Eli Lilly and Company by 24.9% in the 1st quarter. Covestor Ltd now owns 426 shares of the company's stock worth $352,000 after acquiring an additional 85 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Eli Lilly and Company by 25.8% in the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock worth $14,866,000 after acquiring an additional 3,696 shares in the last quarter. Finally, Boston Trust Walden Corp raised its position in shares of Eli Lilly and Company by 1.2% in the 1st quarter. Boston Trust Walden Corp now owns 3,284 shares of the company's stock worth $2,712,000 after acquiring an additional 40 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of the business's stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Morgan Stanley lowered their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday, October 3rd. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Berenberg Bank reaffirmed a "hold" rating and issued a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. JPMorgan Chase & Co. decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating for the company in a research report on Tuesday, September 16th. Finally, The Goldman Sachs Group boosted their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a research report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $939.12.

Eli Lilly and Company Price Performance

LLY stock opened at $803.53 on Friday. The company has a market capitalization of $760.51 billion, a P/E ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The business has a 50-day simple moving average of $753.09 and a two-hundred day simple moving average of $765.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.